Ebenbuild Secures $2.3M Grant to Advance Digital Twin Lung Simulations for Next-Gen Respiratory Care

Ebenbuild is excited to announce a significant funding milestone, having raised $2,300,000 to propel the next phase of its innovative journey in digital health technology.

At the forefront of healthcare innovation, Ebenbuild specializes in developing precise, patient-specific simulation models of lungs—often referred to as digital twins—by leveraging advanced physics-based simulation techniques, artificial intelligence, and cutting-edge data science.

This new round of funding will be strategically allocated to further refine and expand this state-of-the-art digital toolset, which is designed to empower clinicians, physicians, decision makers in the life sciences industry, and researchers by offering a much clearer understanding of respiratory diseases and individual patient pathophysiology.

With this infusion of capital, the company aims to accelerate the development of a new class of products and services, including in silico trials that promise to de-risk and speed up the development process of inhaled drugs, as well as personalized treatment options geared toward improving survival and recovery rates in conditions such as Acute Respiratory Distress Syndrome that affect millions each year.

This strategic investment comes at a crucial time, as demand for more precise and adaptable healthcare solutions continues to rise.

By bridging the gap between comprehensive patient data and tailored medical interventions, Ebenbuild is poised to reshape treatment paradigms and contribute significantly to the evolution of respiratory care worldwide.

The enthusiasm surrounding this funding round underscores the strong confidence in Ebenbuild’s mission to offer deep insights into complex lung conditions through its groundbreaking digital twins, ultimately transforming the landscape of digital health and patient-centric care.